The goal of this Project is to develop and apply a new methodology that characterizes deployment of microbicidal formulations in women, and that elucidates biophysical mechanisms which govern deployment -- the spreading and retention of formulations over the intra-vaginal epithelial surfaces. The precise nature of deployment that is sufficient for prophylaxis against STI pathogens is unknown, and there is little knowledge of deployment characteristics of any formulation in women. This Project will thus obtain unprecedented knowledge and data. A new intravaginal optical sensing device, developed by the applicant?s laboratory, will be employed to quantitate carrageenan formulation coating thickness distributions in women. A series of studies will contrast important biological and biophysical factors, e.g., time and motion after formulation application, cycle phase and simulated coitus. The results will contribute immediately to evaluation of the novel carrageenan formulations, and determinations of which one(s) have the greatest potential as microbicides for women. This Project will also employ objective biophysical analysis, experimental and theoretical, to develop relationships between formulation properties and deployment characteristics. At present there is virtually no such knowledge, nor methodology to obtain it. The apliocant's approach is to develop a set of integrated in vitro experimental simulations of salient bio-fluid mechanical processes that produce formulation flow and retention within the vagina. For each such process the applicant will also develop fluid mechanical theory that predicts biologically important endpoints (e.g., formulation spreading rates, layer thicknesses and properties) using measured values of formulation properties as inputs. Correspondence between theory and experiment provide a means of physical validation of the in vitro methods. The final goal of the Project will be to link the in vitro methods with the in vivo results, and to create and apply a biophysical test bed for evaluation and optimization of the novel carrageenan formulations. This will provide an objective and accurate means of relating formulation properties directly to microbicidal function. It will be an unprecedented, but necessary component of the overall biological and biophysical evaluation of the novel carrageenan formulations.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
1P01HD041752-01
Application #
6550764
Study Section
Special Emphasis Panel (ZHD1)
Project Start
2001-09-27
Project End
2005-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Population Council
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10017
Fernandez-Romero, Jose A; Thorn, Mitchell; Turville, Stuart G et al. (2007) Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 34:9-14
Morrow, Gavin; Vachot, Laurence; Vagenas, Panagiotis et al. (2007) Current concepts of HIV transmission. Curr HIV/AIDS Rep 4:29-35
Fang, L; Meyers, C; Budgeon, L R et al. (2006) Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 347:28-35
Fang, L; Budgeon, L R; Doorbar, J et al. (2006) The human papillomavirus type 11 E1/E4 protein is not essential for viral genome amplification. Virology 351:271-9
Peretti, Silvia; Shaw, Andrew; Blanchard, James et al. (2005) Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses. Blood 106:1305-13
Turville, Stuart G; Santos, John J; Frank, Ines et al. (2004) Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103:2170-9
Eisenblatter, Martin; Stahl-Hennig, Christiane; Kuate, Seraphin et al. (2004) Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques. Vaccine 22:3295-302
Kish, Tina M; Ward, Margaret G; Welsh, Patricia A et al. (2003) HIV-1 infection in a small animal human vaginal xenograft model. J Acquir Immune Defic Syndr 34:454-60
Fang, L; Ward, M G; Welsh, P A et al. (2003) Suppression of human papillomavirus gene expression in vitro and in vivo by herpes simplex virus type 2 infection. Virology 314:147-60
Teleshova, Natalia; Frank, Ines; Pope, Melissa (2003) Immunodeficiency virus exploitation of dendritic cells in the early steps of infection. J Leukoc Biol 74:683-90